Cargando…
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
BACKGROUND: Several companion diagnostic (CDx) tests for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have been approved. In our institute, the CDx test for EGFR‐TKIs was changed from the Therascreen test (Therascreen) to the Cobas EGFR v2 test (Cobas) because only Cobas w...
Autores principales: | Uchibori, Ken, Takano, Natsuki, Manabe, Ryo, Tsugitomi, Ryosuke, Ogusu, Shinsuke, Tozuka, Takehiro, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Ariyasu, Ryo, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952781/ https://www.ncbi.nlm.nih.gov/pubmed/33528892 http://dx.doi.org/10.1111/1759-7714.13797 |
Ejemplares similares
-
Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021) -
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
por: Ariyasu, Ryo, et al.
Publicado: (2020) -
Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023) -
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer
por: Low, Siew-Kee, et al.
Publicado: (2022) -
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
por: Amino, Yoshiaki, et al.
Publicado: (2023)